Top Markets
#1 DogBull DogBull +54.88%
#2 Siren Siren +31.44%
#3 OriginTrail OriginTrail +17.48%
#4 Yield Basis Yield Basis +10.34%
#5 龙虾 (Lobster) 龙虾 (Lobster) +8.85%
#6 MetYa MetYa +8.10%
#7 LayerZero LayerZero +7.76%
#8 COTI COTI +7.55%
#9 Stargate Finance Stargate Finance +7.55%
#10 Cysic Cysic +7.12%
Coin of the day
DogBull DogBull
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
3D Medicines Inc. 3D Medicines Inc.

3D Medicines Inc.

1244
Classement en actions #22092
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a... Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Prix de l'action
$0.38441832
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$94.54M
Changement (1 jour)
-12.13%
Changement (1 an)
-62.78%
Pays
CN
Échange 3D Medicines Inc. (1244)

Catégorie

Healthcare
Bénéfices pour 3D Medicines Inc. (1244)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de 3D Medicines Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour 3D Medicines Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH